Poland’s regulated market for prescription-based flower and extracts grew quickly—and then hit a hard compliance “reset” in late 2024 and throughout 2025. Two forces are converging:
- A telemedicine prescribing crackdown aimed at so‑called “prescription mills” (“receptomaty”), which has reportedly reduced the volume of prescriptions.
- Intensifying EU Novel Food and consumer‑protection enforcement against ingestible CBD products marketed online without authorization—often visible in RASFF notices and follow‑up measures.
For operators, the headline is simple: Poland is not “closing” the market, but it is raising the cost of being sloppy. Importers, brand owners, clinics, pharmacies, and online retailers should assume more scrutiny, more documentation requests, and faster delisting actions.
This article is informational only, not legal advice.
Why 2025 looks different in Poland
Poland’s regulators are responding to a broader healthcare integrity problem: remote prescribing at scale, sometimes with minimal clinical assessment, and an e‑prescription system that can be exploited if governance is weak. At the same time, Polish authorities operate within EU food law, where CBD extracts for ingestion generally fall under Novel Food rules unless a valid authorization applies.
In practice, 2025 is a year where:
- Prescription workflows must look like conventional medicine (documented diagnosis, patient history, follow‑up, monitoring).
- Pharmacy dispensing is expected to align tightly with controlled‑substance handling standards.
- CBD ingestible SKUs carry elevated enforcement risk unless clearly outside Novel Food scope or supported by the right regulatory strategy.
Telemedicine crackdown: what changed and why it matters
The policy direction: remote is not “no‑touch”
Industry coverage and legal commentary indicate that Poland moved to limit the ability of specialist clinics to issue prescriptions via teleconsultation without an in‑person examination—especially for controlled medicines. For example, CMS reported that the Ministry of Health discussed changes where only primary care physicians would be able to issue certain prescriptions during an online consultation, reflecting a tightening stance for controlled products.
Market signal: prescriptions reportedly fell after the change
Multiple industry sources cite a notable drop from the peak in October 2024 following the restriction of online prescribing.
While these are not official government statistical releases, they are consistent with the enforcement narrative: remote prescribing is being re‑anchored to clinical accountability and traceable medical justification.
What “compliant telemedicine” should look like in 2025
A compliant model is not simply “video call + e‑prescription.” Clinics should treat remote care as a documentation-heavy medical service with clear triggers for in‑person review.
Key expectations to operationalize:
- Identity verification and patient consent captured in the medical record.
- Intake and anamnesis: prior therapies, contraindications, substance‑use history, mental health screening where relevant.
- Medical justification for therapy choice, dose form, and quantity.
- In‑person examination pathway: a documented policy defining when first visit must be in person, when follow‑ups may be remote, and when escalation is required.
- Monitoring and follow‑up: adverse event reporting, effectiveness tracking, and a clear discontinuation plan.
- Anti‑abuse controls: limits on frequency of renewals, flags for multi‑provider shopping, and internal audit logs.
If your organization operates clinics (or partners with them), your compliance posture should be able to answer: “Why was this prescription appropriate for this patient, on this date, via this modality?”
Mapping prescription workflows: in‑person vs. telemedicine
Workflow A (preferred under heightened scrutiny): in‑person initiation
A conservative pathway many operators are adopting:
- In‑person first consult with full history, exam (where relevant), and risk screening.
- Baseline documentation recorded: indication, prior therapies, treatment goals, informed consent.
- E‑prescription issuance after clinical decision.
- Remote follow‑ups allowed only for stable patients, with defined intervals.
- Periodic re‑evaluation in person (e.g., every X months) depending on patient risk profile.
Why it matters: if audited, the first in‑person exam provides a strong anchor for medical necessity.
Workflow B (higher risk): telemedicine initiation
If telemedicine initiation is still used in limited cases, the compliance burden goes up:
- Stronger identity checks (document scan + live verification).
- More structured clinical questionnaires (and physician review, not automated scoring only).
- Mandatory pharmacy coordination and patient education steps.
- Shorter initial supply and earlier follow‑up.
Brands should avoid building demand forecasts around “instant online prescriptions.” That channel is now structurally less reliable.
Pharmacy dispensing controls: what pharmacies and suppliers should expect
Poland’s model routes products through pharmacies, and controlled‑substance expectations cascade down to dispensing and recordkeeping.
E‑prescriptions for controlled medicines
Poland has continued modernizing its e‑prescription environment, and reporting indicates that prescriptions for narcotic/psychotropic products are issued electronically under tightened rules.
Practical controls that affect importers and MAHs
Even if you don’t operate the pharmacy, your supply chain will be judged by how “clean” it is:
- Batch documentation must match what pharmacies receive (CoA, release documents, packaging specs).
- Stable availability matters: shortages invite substitution and patient complaints, which increases regulator attention.
- Pharmacovigilance‑style readiness: pharmacies will escalate quality issues; importers should have complaint handling and investigation workflows.
Importers: documentation and authorizations that cannot be “patched later”
Poland’s import and distribution of controlled substances sits within a licensing framework overseen by the Chief Pharmaceutical Inspectorate (GIF / Chief Pharmaceutical Inspectorate).
GIF: controlled substances approvals and licenses
GIF’s official information for entrepreneurs and the controlled substances area highlights its role in issuing approvals for import or intra‑Community acquisition of narcotic drugs and psychotropic substances.
What importers should have organized (and retrievable fast):
- Corporate authorizations: wholesale distribution authorization(s) and any required controlled‑substance specific permissions.
- Transaction permissions: import/intra‑Community acquisition approvals where applicable.
- GMP/GDP evidence across the chain (manufacturer, QP release if relevant, transport qualification, temperature controls).
- Product specifications: full qualitative/quantitative composition, stability, contaminants limits, and validated analytical methods.
- Traceability: lot-to-lot reconciliation, destination pharmacy/wholesaler records, deviation logs.
URPL: marketing authorization and product status discipline
Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) is the authority maintaining the Register of Medicinal Products admitted to trade.
The strategic takeaway: do not blur categories. A product should be clearly positioned and documented as a medicinal product, a medical device, a cosmetic, or a food supplement/food—and your labels, claims, and online listings must match that classification.
CBD ingestibles: Poland’s Novel Food enforcement posture is hardening
Under Regulation (EU) 2015/2283, a Novel Food requires pre‑market authorization if it was not consumed to a significant degree in the EU before 15 May 1997. EU institutions have long treated extracts containing cannabinoids (including CBD) as Novel Food absent a demonstrated history of consumption.
This is why “CBD oil as a food supplement” remains a high‑risk category in most EU countries, including Poland.
RASFF signals: unauthorized CBD products marketed online from Poland
The RASFF Window (EU Rapid Alert System for Food and Feed) provides concrete examples of enforcement focus. In 2025, notifications explicitly reference unauthorized Novel Food CBD offered for sale online from Poland, with measures including sales bans.
For brands, this matters even if you are not based in Poland: cross‑border e‑commerce makes your Polish listing visible to other Member States, and enforcement can be triggered externally.
EFSA: safety scrutiny is increasing, not fading
One reason the Novel Food pathway remains difficult is that EFSA has repeatedly highlighted data gaps around CBD safety. EFSA’s updated communication sets a provisional safe intake level while underscoring ongoing uncertainties.
Even if your dossier strategy is strong, your commercial plan must account for:
- conservative exposure assumptions,
- toxicology package expectations,
- validated specs for impurities (including THC and minor cannabinoids),
- and consistency across batches and extraction methods.
What an EU Novel Food dossier typically needs (and where brands fail)
A Novel Food application is not a “formality.” It is a technical file intended to support EU‑wide authorization.
Common dossier elements to plan for:
- Identity and characterization: source material, extraction/manufacturing process, and compositional data.
- Specifications: assay, impurity limits, residual solvents, pesticides, heavy metals, microbiology.
- Stability data: shelf life under proposed storage conditions and in relevant matrices.
- Proposed uses and use levels: target population, daily intake, categories of foods.
- ADME and toxicology: addressing liver effects, endocrine and neurological endpoints, reproductive concerns, and interactions.
- Human data where available, plus a plan to fill gaps.
Where brands commonly fail in Poland (and get delisted):
- Selling ingestible CBD while calling it a “supplement” without a credible Novel Food authorization pathway.
- Using vague ingredient descriptors (“hemp extract”) while marketing cannabinoid content.
- Making disease or drug‑like claims that trigger medicinal product classification risk.
Poland-specific food supplement realities: notification is not approval
Poland’s Chief Sanitary Inspectorate (GIS) supervises food supplements. Market entry often involves notification rather than a formal pre‑approval, but that does not protect products that violate Novel Food or claims rules.
In other words: you can notify a supplement and still be investigated, challenged, or removed.
A practical overview of the notification concept (non‑official but consistent with practice) is widely described by Polish regulatory service providers, emphasizing that notification can trigger verification and withdrawals.
The commercial takeaway: treat GIS notification as a starting point for scrutiny, not a compliance shield.
Retailer and marketplace risk: delisting is now a core compliance outcome
In 2025, many brands underestimate the most immediate enforcement consequence: retailer delisting and payment/fulfillment disruption.
Triggers for delisting in Poland commonly include:
- Novel Food risk (ingestible CBD formats)
- implied medical claims (“anxiety,” “pain,” “insomnia,” “inflammation,” “ADHD,” etc.)
- incomplete Polish-language labeling and missing mandatory food supplement statements
- lab report mismatches (label vs. actual content)
Once delisted, reinstatement typically requires more than “updated copy.” Expect requests for:
- product classification rationale,
- full composition and specs,
- proof of compliant status for the ingredient,
- and a claims/marketing compliance memo.
Contingency planning for brands and importers (what to change now)
In Poland, the fastest way to reduce enforcement exposure is to stop straddling categories.
Actions:
- If you sell ingestibles, evaluate whether you can pivot to hemp seed-derived foods (seed oil, flour, etc.) that are more clearly established—without cannabinoid claims.
- If you remain in ingestibles, align your roadmap with a Novel Food authorization strategy and assume interim risk.
- For topicals, align with the EU Cosmetics Regulation compliance stack (PIF, CPSR, CPNP notification, INCI, claims substantiation).
2) Claims scrub: remove medical language and implied therapeutic promises
Your website, product page, customer service scripts, influencer briefs, and FAQs should be reviewed to remove:
- disease references,
- drug comparison language,
- “clinically proven” without substantiation,
- and dosage instructions that resemble medicinal directions.
Treat claims compliance as part of cannabis compliance in the broad sense: enforcement often begins with marketing.
3) Build a “Poland-ready” compliance pack for every SKU
For each product, maintain a shareable folder containing:
- classification decision (food vs cosmetic vs medicinal)
- labels (Polish language version, with mandatory statements)
- COAs from an accredited lab, with batch traceability
- specifications and stability summary
- GMP/GDP documents where relevant
- adverse event / complaint SOP
This reduces downtime when platforms, distributors, or inspectors ask questions.
4) Customer-care messaging: prepare for “availability shock” without panic
The telemedicine shift and delisting events can create sudden drops in access.
Brands that handle this well:
- publish neutral, non-medical messaging about “regulatory updates,”
- avoid encouraging workarounds,
- provide pharmacy-finder support where allowed,
- and train support teams to avoid prohibited claims.
5) Scenario plan your Poland 2026 forecast
Plan for at least three operational scenarios:
- Base case: prescriptions stabilize at a lower telemedicine-driven baseline; pharmacy channel remains primary.
- Restricted case: further tightening of remote initiation; clinic partners must expand in-person capacity.
- Enforcement spike: more RASFF-linked actions and GIS follow-ups on online listings; higher delisting rates.
Compliance takeaways (business + consumer)
For businesses
- The Poland medical cannabis CBD novel food 2025 environment rewards medical-grade governance and punishes growth hacks.
- Clinics should assume audits and design workflows where in-person initiation is the default.
- Importers must treat GIF/URPL documentation as a real-time operational requirement, not a back-office formality.
- CBD ingestibles face elevated risk without a credible Novel Food strategy; RASFF notices show real enforcement outcomes.
For consumers
- Expect fewer “instant” online prescriptions and more traditional medical pathways.
- Be cautious with ingestible CBD products sold online: enforcement actions can lead to sudden product unavailability.
Stay ahead with CannabisRegulations.ai
If you operate in Poland—or sell into Poland via EU e‑commerce—2025’s reset is a reminder that compliance is your distribution strategy. Use https://cannabisregulations.ai/ to track regulatory updates, map compliant prescription and dispensing workflows, and build documentation checklists that hold up under scrutiny.
Informational only; consult qualified counsel for legal advice.
